Ioannis Mantzaris
@YannisMantz
Followers
101
Following
54
Media
0
Statuses
6
MD, MS, Associate Professor, @Montefiore/Einstein, acute leukemias, clinical research
New York, USA
Joined December 2020
RT @Amitvermamds: Crispr modified CD70 allo CARs against T cell malignancies. Trial co-led by our outstanding Alex Sica in @TheLancetOncol….
thelancet.com
In patients with heavily pretreated T-cell lymphoma, CTX130 showed manageable safety and a promising objective response rate. This study shows that allogeneic, readily available CAR T cells can be...
0
10
0
🔥 Excited for our Phase 1 study Ven + 7+3 for Newly Diagnosed AML.demonstrating 85% CR (86% MRD-neg).@BloodJournal @ MontefioreNYC @EinsteinMed @MontefioreNYC .Eric J. Feldman @MendelGoldfing2.@mkonople @Amitvermamds @aditishasMD @Gritsman_lab .#leusm.
ashpublications.org
Key PointsVen can be safely used in combination with 7+3 chemotherapy for remission induction in patients with newly diagnosed AML.Ven plus 7+3 chemotherap
5
17
63
RT @MendelGoldfing2: 🔥 Our clinical trial of metronomic low-dose decitabine-ven in frontline MDS/ AML shows low tox, high efficacy & high….
pubmed.ncbi.nlm.nih.gov
A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall...
0
23
0